Eberjoint 40 Prefilled Intra-Articular Syringe Hyaluronic Acid 2% 2Ml
€60,00
Skip to product information
DITTA: EBERLIFE FARMACEUTICI SPA
Eberjoint 40 Prefilled Intra-Articular Syringe Hyaluronic Acid 2% 2Ml
€60,00
MINSAN: 980529693
EAN:
EBERJOINT CROSS 75
Description
Eberjoint cross 75 is a buffered physiological solution containing 2.5% cross-linked hyaluronic acid with significant viscoelastic properties.
Sodium hyaluronate is a fundamental component of synovial fluid, being responsible for its specific viscoelastic properties.
Syringe sterilized with moist heat.
Components
Cross-linked hyaluronic acid; sodium chloride, phosphate buffer, water for injections.
Directions for use
Inject 3 ml of product intra-articularly every 6 months, unless otherwise advised by a doctor and depending on the patient's condition.
At the doctor's discretion, and according to the patient's health status, it is possible to treat multiple joints at the same time.
The volumetric graduation shown on the syringes is indicative.
Aspirate any synovial effusion before proceeding with the injection of Eberjoint cross 75. Remove the cap from the syringe, taking particular care to avoid contact with the opening.
Insert an appropriately sized needle (18 to 22 G), screwing it on firmly to ensure a watertight seal and prevent leakage of the solution.
Inject the device only into the synovial space, at room temperature and under strictly aseptic conditions.
Components
Sodium chloride, phosphate buffer, water for injections.
Warnings
Do not use after the expiry date indicated on the packaging.
Do not use if the packaging is open or damaged.
The area where the injection is administered must be on healthy skin.
Do not inject intravascularly.
Do not inject into the knee joint in the presence of venous or lymphatic stasis in the limb.
Do not inject outside the joint cavity, into the synovial tissue, or into the joint capsule.
Do not administer in the presence of severe intra-articular effusions.
Eberjoint cross 75 must not be injected in the presence of infections, inflammations, or skin conditions in the area to be treated.
After the intra-articular injection, advise the patient to avoid all intense physical activities and to resume normal activities only after a few days.
The contents of the pre-filled syringe are sterile.
The outer surface of the syringe is not sterile.
Do not resterilize. The device is for single use.
Extra-articular infiltration may cause local side effects.
Symptoms such as pain, a sensation of heat, redness, or swelling may occur at the injection site. In such cases, it is useful to apply
Eberjoint cross 75 is a buffered physiological solution containing 2.5% cross-linked hyaluronic acid with significant viscoelastic properties.
Sodium hyaluronate is a fundamental component of synovial fluid, being responsible for its specific viscoelastic properties.
Syringe sterilized with moist heat.
Components
Cross-linked hyaluronic acid; sodium chloride, phosphate buffer, water for injections.
Directions for use
Inject 3 ml of product intra-articularly every 6 months, unless otherwise advised by a doctor and depending on the patient's condition.
At the doctor's discretion, and according to the patient's health status, it is possible to treat multiple joints at the same time.
The volumetric graduation shown on the syringes is indicative.
Aspirate any synovial effusion before proceeding with the injection of Eberjoint cross 75. Remove the cap from the syringe, taking particular care to avoid contact with the opening.
Insert an appropriately sized needle (18 to 22 G), screwing it on firmly to ensure a watertight seal and prevent leakage of the solution.
Inject the device only into the synovial space, at room temperature and under strictly aseptic conditions.
Components
Sodium chloride, phosphate buffer, water for injections.
Warnings
Do not use after the expiry date indicated on the packaging.
Do not use if the packaging is open or damaged.
The area where the injection is administered must be on healthy skin.
Do not inject intravascularly.
Do not inject into the knee joint in the presence of venous or lymphatic stasis in the limb.
Do not inject outside the joint cavity, into the synovial tissue, or into the joint capsule.
Do not administer in the presence of severe intra-articular effusions.
Eberjoint cross 75 must not be injected in the presence of infections, inflammations, or skin conditions in the area to be treated.
After the intra-articular injection, advise the patient to avoid all intense physical activities and to resume normal activities only after a few days.
The contents of the pre-filled syringe are sterile.
The outer surface of the syringe is not sterile.
Do not resterilize. The device is for single use.
Extra-articular infiltration may cause local side effects.
Symptoms such as pain, a sensation of heat, redness, or swelling may occur at the injection site. In such cases, it is useful to apply